Orchard Therapeutics PLC (ORTX)

NASDAQ
1.270
-0.080(-5.93%)
After Hours
1.280
+0.010(+0.787%)
- Real-time Data
  • Volume:
    514,171
  • Bid/Ask:
    1.280/1.330
  • Day's Range:
    1.270 - 1.410

ORTX Overview

Prev. Close
1.35
Day's Range
1.27-1.41
Revenue
1.19M
Open
1.38
52 wk Range
1.27-9.08
EPS
-1.22
Volume
514,171
Market Cap
159.38M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
1,006,965
P/E Ratio
-
Beta
-
1-Year Change
-73.37%
Shares Outstanding
125,498,931
Next Earnings Date
Mar 02, 2022
What is your sentiment on Orchard Therapeutics PLC?
or
Market is currently closed. Voting is open during market hours.

Orchard Therapeutics PLC Company Profile

Employees
224

Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company’s gene therapy approach seeks to transform a patient’s hematopoietic stem cells into a gene-modified cellular drug product to treat the patient’s disease through a single administration. It provides Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company’s clinical development products comprise OTL-101 for the treatment of ADA-SCID; OTL-200 to treat metachromatic leukodystrophy; OTL-103 for the treatment of Wiskott-Aldrich syndrome; OTL-102 for X-linked chronic granulomatous disease; and OTL-300 for transfusion-dependent beta-thalassemia. Its preclinical programs include OTL-203 for mucopolysaccharidosis type I, OTL-201 for mucopolysaccharidosis type MPS-IIIA, and OTL-202 for mucopolysaccharidosis type IIIB. The company has a strategic collaboration agreement with Pharming Group N.V. for research, development, manufacturing, and commercialization of OTL-105, an investigational ex vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. The company was formerly known as Orchard Rx Limited. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom.

Read More

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellStrong Sell
Technical IndicatorsStrong SellStrong SellStrong SellStrong SellStrong Sell
SummaryStrong SellStrong SellStrong SellStrong SellStrong Sell
  • What's going on?
    0
    • Any target price?
      0
      • I like the Co. But don't trust its CEO, no transparent at all levels and high dilution possibilities
        0
    • Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that it has executed a securities purchase agreement to raise gross proceeds of $150 Million
      0
      • Orchard Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
        0
        • Orchard Therapeutics Receives EC Approval for Libmeldy™ for the Treatment of Early-Onset Metachromatic Leukodystrophy (MLD)
          2
          • Sky is the limit.. Head and shoulders are clear
            0
            • I think ORTX is headed towards record highs after the EMA new approvals. We can easily see it trading at $16 very soon according to couple of sell side research reports.
              0
              • I think its flying to $16 very soon
                0
                • Any hope for this crippled stock?
                  0
                  • Any target price?
                    0
                    • 4.84
                      0
                    • 16$ at dec 2021
                      0
                    • IDAN PARNEShahahaha
                      0
                  • Guys, what time trade start?
                    0
                    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.